MCL1 and lymphoid neoplasm: AZD4573, a clinical congener of AZ5576, was shown to suppress transcription of the pro-survival proteins Mcl-1 and Bfl-1/A1 in lymphoid tumors, and exhibited anti-tumor effects in AML models in vivo via an Mcl-1 dependent mechanism [6, 7].